p95-HER2 and trastuzumab resistance in metastatic breast cancer; is immunohistochemistry appropriate?


Kocar M., Bozkurtlar E. , Telli F., Yumuk F. , Kaya H. , Kocar H., ...More

JOURNAL OF BUON, vol.19, pp.245-249, 2014 (Journal Indexed in SCI) identifier

  • Publication Type: Article / Article
  • Volume: 19
  • Publication Date: 2014
  • Title of Journal : JOURNAL OF BUON
  • Page Numbers: pp.245-249

Abstract

Purpose: Unraveling the mechanisms underlying the resistance to trastuzumab is important for amending the prognosis of patients with human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer. Experimentally, it has been shown that p95-HER2 positive breast tumors are resistant to trastuzumab. The aim of this study was to investigate the predictive and prognostic importance of p95-HER2 expression by immunohistochemistry in HER2-positive metastatic breast cancer patients treated with trastuzumab.